image
Chimerix, Inc. CMRX
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 8.52
-0.117 %
$ 799 M
Market Cap
-8.61
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CMRX stock under the worst case scenario is HIDDEN Compared to the current market price of 8.52 USD, Chimerix, Inc. is HIDDEN

CMRX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CMRX stock under the base case scenario is HIDDEN Compared to the current market price of 8.52 USD, Chimerix, Inc. is HIDDEN

CMRX Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one CMRX stock under the best case scenario is HIDDEN Compared to the current market price of 8.52 USD, Chimerix, Inc. is HIDDEN

CMRX Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart CMRX

image
1M 1%
6M 875%
1Y 787%
3Y 78%
5Y 453%
All
$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0$1.0$1.0$0.0$0.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
212 K REVENUE
-34.57%
Growth Rates
1Year -34.57%
3Years -52.51%
5Years -55.77%
7Years -35.36%
10Years -25.53%
-96.6 M OPERATING INCOME
-3.76%
Growth Rates
1Year -3.76%
3Years 17.73%
5Years -52.06%
7Years -4.26%
10Years -5.07%
-88.4 M NET INCOME
-7.66%
Growth Rates
1Year -7.66%
3Years 20.09%
5Years 4.72%
7Years -3.18%
10Years -4.07%
-75 M OPERATING CASH FLOW
-8.52%
Growth Rates
1Year -8.52%
3Years 9.13%
5Years 0.05%
7Years -5.92%
10Years -4.76%
71.3 M INVESTING CASH FLOW
1.02%
Growth Rates
1Year 1.02%
3Years 53.51%
5Years 46.33%
7Years 23.33%
10Years 9.36%
7.05 M FINANCING CASH FLOW
2188.64%
Growth Rates
1Year 2188.64%
3Years -60.27%
5Years 82.84%
7Years 36.98%
10Years -29.28%
57 K REVENUE
119.23%
Growth Rates
1Year -34.57%
3Years -52.51%
5Years -55.77%
7Years -35.36%
10Years -25.53%
-24.6 M OPERATING INCOME
0.97%
Growth Rates
1Year -3.76%
3Years 17.73%
5Years -52.06%
7Years -4.26%
10Years -5.07%
-23 M NET INCOME
-0.33%
Growth Rates
1Year -7.66%
3Years 20.09%
5Years 4.72%
7Years -3.18%
10Years -4.07%
-19.3 M OPERATING CASH FLOW
6.05%
Growth Rates
1Year -8.52%
3Years 9.13%
5Years 0.05%
7Years -5.92%
10Years -4.76%
20 M INVESTING CASH FLOW
-29.49%
Growth Rates
1Year 1.02%
3Years 53.51%
5Years 46.33%
7Years 23.33%
10Years 9.36%
6.7 M FINANCING CASH FLOW
3666.85%
Growth Rates
1Year 2188.64%
3Years -60.27%
5Years 82.84%
7Years 36.98%
10Years -29.28%
Balance Sheet Chimerix, Inc.
image
Current Assets 136 M
Cash & Short-Term Investments 31 M
Receivables 57 K
Other Current Assets 105 M
Non-Current Assets 10.1 M
Long-Term Investments 8.48 M
PP&E 1.37 M
Other Non-Current Assets 214 K
21.27 %71.81 %5.80 %Total Assets$146.0m
Current Liabilities 23.9 M
Accounts Payable 3.94 M
Short-Term Debt 0
Other Current Liabilities 19.9 M
Non-Current Liabilities 458 K
Long-Term Debt 458 K
Other Non-Current Liabilities 0
16.19 %81.93 %Total Liabilities$24.3m
EFFICIENCY
Earnings Waterfall Chimerix, Inc.
image
Revenue 212 K
Cost Of Revenue 0
Gross Profit 212 K
Operating Expenses 96.8 M
Operating Income -96.6 M
Other Expenses -8.18 M
Net Income -88.4 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)212k0212k(97m)(97m)8m(88m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
Averages
1Year 100.00%
3Years 99.56%
5Years -39.89%
7Years -153.20%
10Years -380.92%
-45550.47% OPERATING MARGIN
-45550.47%
Averages
1Year -45550.47%
3Years -24817.59%
5Years -16808.69%
7Years -12132.51%
10Years -8899.79%
-41691.98% NET MARGIN
-41691.98%
Averages
1Year -41691.98%
3Years -22173.65%
5Years -16046.12%
7Years -11797.21%
10Years -8659.03%
-72.64% ROE
-72.64%
Averages
1Year -72.64%
3Years -16.05%
5Years -96.07%
7Years -96.77%
10Years -77.20%
-60.54% ROA
-60.54%
Averages
1Year -60.54%
3Years -12.50%
5Years -68.33%
7Years -74.79%
10Years -61.33%
-79.06% ROIC
-79.06%
Averages
1Year -79.06%
3Years -50.09%
5Years -101.86%
7Years -75.98%
10Years -62.61%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Chimerix, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -88.4 M
Depreciation & Amortization 94 K
Capital Expenditures -287 K
Stock-Based Compensation 9.48 M
Change in Working Capital 7.44 M
Others -1.61 M
Free Cash Flow -75.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Chimerix, Inc.
image
Wall Street analysts predict an average 1-year price target for CMRX of $8.55 , with forecasts ranging from a low of $8.55 to a high of $8.55 .
CMRX Lowest Price Target Wall Street Target
8.55 USD 0.35%
CMRX Average Price Target Wall Street Target
8.55 USD 0.35%
CMRX Highest Price Target Wall Street Target
8.55 USD 0.35%
Price
Max Price Target
Min Price Target
Average Price Target
99887766554433221100May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Chimerix, Inc.
image
Sold
0-3 MONTHS
91.1 K USD 5
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.06 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Biotech Stocks Q1 2025 Recap: Winners And Underperformers Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone. seekingalpha.com - 1 week ago
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 globenewswire.com - 3 weeks ago
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharmaceuticals plc. (NasdaqGS: JAZZ). Under the terms of the proposed transaction, shareholders of Chimerix will receive $8.55 in cash for each share of Chimerix that they own. KSF is seeking to determine whether this consideration and the process that led to. businesswire.com - 1 month ago
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix's Board of Directors granted an inducement award to a new employee of non-statutory stock options to purchase up to a total of 70,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing rule 5635(c)(4). globenewswire.com - 1 month ago
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholders. globenewswire.com - 1 month ago
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog. zacks.com - 1 month ago
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More CMRX and JAZZ are in the spotlight this week following an acquisition agreement. zacks.com - 1 month ago
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024. zacks.com - 1 month ago
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX NEW YORK , March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Chimerix, Inc. (NASDAQ: CMRX ), relating to the proposed merger with Jazz Pharmaceuticals. prnewswire.com - 1 month ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders NEW YORK , March 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chimerix, Inc. (NASDAQ: CMRX)'s  sale to Jazz Pharmaceuticals plc for $8.55 per share in cash. If you are a Chimerix shareholder, click here to learn more about your rights and options. prnewswire.com - 1 month ago
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline On Tuesday, Jazz Pharmaceuticals plc JAZZ agreed to acquire Chimerix Inc CMRX for $8.55 per share in cash, representing a total consideration of approximately $935 million. benzinga.com - 1 month ago
Jazz Pharmaceuticals to buy Chimerix for $935 million Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million to gain access to its experimental drug to treat a rare brain tumor, the companies said on Wednesday. reuters.com - 1 month ago
8. Profile Summary

Chimerix, Inc. CMRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 799 M
Dividend Yield 0.00%
Description Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Contact 2505 Meridian Parkway, Durham, NC, 27713 https://www.chimerix.com
IPO Date April 11, 2013
Employees 79
Officers Dr. Joshua E. Allen Ph.D. Chief Scientific Officer Mr. Michael T. Andriole M.B.A. Chief Executive Officer, President & Director Dr. Allen S. Melemed M.B.A., M.D. Chief Medical Officer Dr. Roy W. Ware M.B.A., Ph.D. Chief Manufacturing & Technology Officer Mr. David Jakeman CPA Vice President of Accounting & Finance Mr. Thomas J. Riga Chief Operating & Commercial Officer Dr. Michael A. Alrutz J.D., Ph.D. Senior Vice President, General Counsel & Corporate Secretary Ms. Michelle LaSpaluto Chief Financial Officer